| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$125.85 |
| 52 Week High | US$134.63 |
| 52 Week Low | US$99.14 |
| Beta | 0.39 |
| 11 Month Change | -5.32% |
| 3 Month Change | -4.08% |
| 1 Year Change | 19.55% |
| 33 Year Change | 63.59% |
| 5 Year Change | 50.38% |
| Change since IPO | 11,086.67% |
Recent News & Updates
Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Jul 24Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Jul 18
Merck: Positive Developments, But Watch The Q2 Earnings
Jul 12Recent updates
Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Jul 24Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Jul 18Merck: Positive Developments, But Watch The Q2 Earnings
Jul 12Merck: Among The Best Health Care GARP Plays Today
Jul 03What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You
Jun 30Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying
Jun 10Merck Stock: Still Discounted To Graham P/E
May 29Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why
May 22Merck Q1: There's Still Room For Growth
May 06Shareholder Returns
| MRK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.3% | 0.004% | -2.4% |
| 1Y | 19.5% | 18.8% | 17.5% |
Return vs Industry: MRK matched the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: MRK exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | US$318.93b |
| Earnings (TTM) | US$2.31b |
| Revenue (TTM) | US$61.40b |
138.2x
P/E Ratio5.2x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | US$61.40b |
| Cost of Revenue | US$15.44b |
| Gross Profit | US$45.96b |
| Other Expenses | US$43.66b |
| Earnings | US$2.31b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 74.85% |
| Net Profit Margin | 3.76% |
| Debt/Equity Ratio | 84.7% |
How did MRK perform over the long term?
See historical performance and comparison